1921
Volume 98, Issue 1
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645

Abstract

Abstract.

We evaluated the therapeutic efficacy of artemether–lumefantrine (AL) fixed-dose combination to treat uncomplicated malaria in Cruzeiro do Sul, Acre State, in the Amazon region of Brazil. Between December 2015 and May 2016, we enrolled 79 patients, 5–79 years old with fever or history of fever in the previous 48 hours and monoinfection confirmed by microscopy. Attempts were made to provide direct observation or phone reminders for all six doses of AL, and patients were followed-up for 28 days. AL was well tolerated, with no adverse events causing treatment interruption. All but one of the 74 patients who completed the 28-day follow-up had an adequate clinical and parasitologic response = 98.6% (95% CI: 93.2-100%). We could not amplify the one isolate of the case with recurrent infection to differentiate between recrudescence and reinfection. Five (6.3%) patients demonstrated persistent asexual parasitemia on Day 3, but none met definition for early treatment failure. We found no mutations in selected gene domains, known to be associated with artemisinin resistance in isolates from Day 0. These results strongly support the continued use of AL as a first-line therapy for uncomplicated malaria in Acre. Routine monitoring of in vivo drug efficacy coupled with molecular surveillance of drug resistance markers remains critical.

Loading

Article metrics loading...

The graphs shown below represent data from March 2017
/content/journals/10.4269/ajtmh.17-0623
2018-01-10
2019-01-23
Loading full text...

Full text loading...

/deliver/fulltext/14761645/98/1/tpmd170623.html?itemId=/content/journals/10.4269/ajtmh.17-0623&mimeType=html&fmt=ahah

References

  1. World Health Organization, 2008. World Malaria Report. Geneva, Switzerland: World Health Organization.
  2. Casos de Malária por mês e espécie parasitária - Brasil 2015–2016: Brazil National Malaria Control Program. 2016.
  3. Fernandes RC, Medina-Acosta E, , 2009. Disseminated BCG disease and the full contraindication to BCG vaccination for children exposed to and/or infected by HIV. Int J Tuberc Lung Dis 13: 11881189, author reply 1189–1190. [Google Scholar]
  4. PAHO, 2011. Strategic Orientation Document on Monitoring the Efficacy and Resistance to Antimalarials in the Current Epidemiological Context. Available at: http://www.paho.org/hq/index.php?option=com_topics&view=readall&cid=5525&Itemid=40757&lang=en. Accessed October 20, 2017.
  5. Vreden SG, Jitan JK, Bansie RD, Adhin MR, , 2013. Evidence of an increased incidence of day 3 parasitaemia in Suriname: an indicator of the emerging resistance of Plasmodium falciparum to artemether. Mem Inst Oswaldo Cruz 108: 968973. [Google Scholar]
  6. Chenet SM, 2016. Independent emergence of the Plasmodium falciparum kelch propeller domain mutant allele C580Y in Guyana. J Infect Dis 213: 14721475. [Google Scholar]
  7. Ariey F, 2014. A molecular marker of artemisinin-resistant Plasmodium falciparum malaria. Nature 505: 5055. [Google Scholar]
  8. Ashley EA, Tracking Resistance to Artemisinin Collaboration , 2014. Spread of artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med 371: 411423. [Google Scholar]
  9. Sidhu AB, Uhlemann AC, Valderramos SG, Valderramos JC, Krishna S, Fidock DA, , 2006. Decreasing pfmdr1 copy number in Plasmodium falciparum malaria heightens susceptibility to mefloquine, lumefantrine, halofantrine, quinine, and artemisinin. J Infect Dis 194: 528535. [Google Scholar]
  10. Lwanga SK, Lemeshow S, , 1991. Sample Size Determination in Health Studies: A Practical Manual. Available at: http://apps.who.int/iris/bitstream/10665/40062/1/9241544058_%28p1-p22%29.pdf.
  11. PAHO, 2003. Resistance to Antimalarials. Available at: http://www.paho.org/hq/index.php?option=com_content&view=article&id=2405%3Aresistance-antimalarials&catid=1233%3Amalaria-program&Itemid=1912&lang=en. Accessed October 20, 2017.
  12. World Health Organization, 2006. The International Pharmacopoeia = Pharmacopoea Internationalis. Geneva, Switzerland: World Health Organization.
  13. Alves-Junior ER, Gomes LT, Assis-Oliveira FB, Silverio-Silva LR, Nery AF, Fontes CJ, , 2014. Quantification of parasite density in 200 microscopic fields underestimates the parasitemia level in malaria patients. Trop Biomed 31: 387391. [Google Scholar]
  14. Lucchi NW, 2014. PET-PCR method for the molecular detection of malaria parasites in a national malaria surveillance study in Haiti, 2011. Malar J 13: 462. [Google Scholar]
  15. Anderson TJ, Su XZ, Bockarie M, Lagog M, Day KP, , 1999. Twelve microsatellite markers for characterization of Plasmodium falciparum from finger-prick blood samples. Parasitology 119: 113125. [Google Scholar]
  16. McCollum AM, Mueller K, Villegas L, Udhayakumar V, Escalante AA, , 2007. Common origin and fixation of Plasmodium falciparum dhfr and dhps mutations associated with sulfadoxine-pyrimethamine resistance in a low-transmission area in South America. Antimicrob Agents Chemother 51: 20852091. [Google Scholar]
  17. Talundzic E, 2015. Selection and spread of artemisinin-resistant alleles in Thailand prior to the global artemisinin resistance containment campaign. PLoS Pathog 11: e1004789. Erratum in: PLoS Pathog 2015;11(4). [Google Scholar]
  18. Talundzic E, Chenet SM, Goldman IF, Patel DS, Nelson JA, Plucinski MM, Barnwell JW, Udhayakumar V, , 2015. Genetic analysis and species specific amplification of the artemisinin resistance-associated kelch propeller domain in P. falciparum and P. vivax. PLoS One 10: e0136099. [Google Scholar]
  19. Gbotosho GO, Folarin OA, Bustamante C, da Silva LH, Mesquita E, Sowunmi A, Zalis MG, Oduola AM, Happi CT, , 2012. Different patterns of pfcrt and pfmdr1 polymorphisms in P. falciparum isolates from Nigeria and Brazil: the potential role of antimalarial drug selection pressure. Am J Trop Med Hyg 86: 211213. [Google Scholar]
  20. Ladeia-Andrade S, de Melo GN, de Souza-Lima Rde C, Salla LC, Bastos MS, Rodrigues PT, Luz F, Ferreira MU, , 2016. No clinical or molecular evidence of Plasmodium falciparum resistance to artesunate-mefloquine in northwestern Brazil. Am J Trop Med Hyg 95: 148154. [Google Scholar]
  21. Alecrim MG, Lacerda MV, Mourao MP, Alecrim WD, Padilha A, Cardoso BS, Boulos M, , 2006. Successful treatment of Plasmodium falciparum malaria with a six-dose regimen of artemether-lumefantrine versus quinine-doxycycline in the western Amazon region of Brazil. Am J Trop Med Hyg 74: 2025. [Google Scholar]
  22. Rahman R, Martin MJ, Persaud S, Ceron N, Kellman D, Musset L, Carter KH, Ringwald P, , 2016. Continued sensitivity of Plasmodium falciparum to artemisinin in Guyana, with absence of kelch propeller domain mutant alleles. Open Forum Infect Dis 3: ofw185. [Google Scholar]
  23. Woodrow CJ, White NJ, , 2017. The clinical impact of artemisinin resistance in Southeast Asia and the potential for future spread. FEMS Microbiol Rev 41: 3448. [Google Scholar]
  24. WHO, 2016. Minutes of the Technical Expert Group (TEG) on Drug Efficacy and Response 10–11 December 2015. Available at: http://www.who.int/malaria/mpac/mar2016/en/. Accessed February 2, 2017.
  25. WHO, 2015. Status Report on Artemisinin Resistance, 2015. Available at: http://whatnot/malaria/publications/atoz/update-artemisinin-resistance-sep2015/en/. Accessed October 20, 2016.
  26. White LJ, 2015. Defining the in vivo phenotype of artemisinin-resistant falciparum malaria: a modelling approach. PLoS Med 12: e1001823. [Google Scholar]
  27. Dahal P, d’Alessandro U, Dorsey G, Guerin PJ, Nsanzabana C, Price RN, Sibley CH, Stepniewska K, Talisuna AO, WWARN Artemisinin Based Combination Therapy (ACT) Africa Baseline Study Group; , 2015. Clinical determinants of early parasitological response to ACTs in African patients with uncomplicated falciparum malaria: a literature review and meta-analysis of individual patient data. BMC Med 13: 212. [Google Scholar]
  28. Tun KM, 2016. Parasite clearance rates in Upper Myanmar indicate a distinctive artemisinin resistance phenotype: a therapeutic efficacy study. Malar J 15: 185. [Google Scholar]
  29. Legrand E, 2012. Discordant temporal evolution of Pfcrt and Pfmdr1 genotypes and Plasmodium falciparum in vitro drug susceptibility to 4-aminoquinolines after drug policy change in French Guiana. Antimicrob Agents Chemother 56: 13821389. [Google Scholar]
  30. Mbaye A, 2016. Selection of N86F184D1246 haplotype of Pfmrd1 gene by artemether-lumefantrine drug pressure on Plasmodium falciparum populations in Senegal. Malar J 15: 433. [Google Scholar]
http://instance.metastore.ingenta.com/content/journals/10.4269/ajtmh.17-0623
Loading
/content/journals/10.4269/ajtmh.17-0623
Loading

Data & Media loading...

  • Received : 04 Aug 2017
  • Accepted : 25 Sep 2017

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error